Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ripasudil

Phase 3Small molecule

KKowa Research Institute, Inc.

Ripasudil is one of 92 small molecule programs targeting Fuchs. It is currently in Phase 3.

3

Indications

7

Total Trials

4

Active Trials

91

Competitors

Pipeline

Status by Indication[3][1]

Indication

FuchsRecruiting

ESSRecruiting

CataractRecruiting

FuchsPhase 3

Recruiting

ESSPhase 1

Recruiting

CataractPhase 3

Recruiting

Competition

Competitive Landscape

63 competitors in Cataract

#DrugCompanyPhaseTrials

Eylea

Avelox

Decadron

AAspen Global Incorporated

Bromday

BBausch Health Americas, Inc.

Toradol

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Lovenox

Voltaren

Cipro

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Fuchs

NCT05289661

Q4 2028

Phase 3Recruiting

Fuchs

NCT05275972

Clinical

Trials by Indication[1]

Fuchs endothelial corneal dystrophy2 trials

A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

Completed·KKowa Research Institute, Inc.·Phase 3·NCT05826353·110 enrolled

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

Completed·KKowa Research Institute, Inc.·Phase 3·NCT05795699·107 enrolled

Fuchs2 trials

Descemet Endothelial Thickness Comparison Trials (DETECT I & II)

Recruiting·SStanford University·Phase 3·NCT05275972·60 enrolled

Descemet Endothelial Thickness Comparison Trials (DETECT I & II)

Active, not recruiting·SStanford University·Phase 3·NCT05289661·160 enrolled

Cataract1 trial

The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery

Recruiting·SSingapore Eye Research Institute·Phase 3·NCT06048380·120 enrolled

ESS1 trial

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

Recruiting·AAsociación para Evitar la Ceguera en México·Phase 1·NCT05636579·12 enrolled

Corneal Edema1 trial

A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Treatment and 14-week Extension, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery

Completed·KKowa Research Institute, Inc.·Phase 3·NCT05528172·330 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Ripasudil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ripasudil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ripasudil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kowa Research Institute, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKowa Research Institute, Inc.

Related News